BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20461751)

  • 1. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
    Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
    Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
    Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
    Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic identification of autoantibodies in sera from patients with ovarian cancer as possible diagnostic biomarkers.
    Yoneyama K; Kojima S; Kodani Y; Yamaguchi N; Igarashi A; Kurose K; Kawase R; Takeshita T; Hattori S; Nagata K
    Anticancer Res; 2015 Feb; 35(2):881-9. PubMed ID: 25667470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
    Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
    Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
    Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
    Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
    Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma.
    Fujita Y; Nakanishi T; Miyamoto Y; Hiramatsu M; Mabuchi H; Miyamoto A; Shimizu A; Takubo T; Tanigawa N
    Cancer Lett; 2008 May; 263(2):280-90. PubMed ID: 18334280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
    Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
    Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.
    Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K
    Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.
    Desmetz C; Bibeau F; Boissière F; Bellet V; Rouanet P; Maudelonde T; Mangé A; Solassol J
    J Proteome Res; 2008 Sep; 7(9):3830-7. PubMed ID: 18683965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
    Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
    Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.
    Kim JH; Herlyn D; Wong KK; Park DC; Schorge JO; Lu KH; Skates SJ; Cramer DW; Berkowitz RS; Mok SC
    Clin Cancer Res; 2003 Oct; 9(13):4782-91. PubMed ID: 14581349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
    Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker.
    He Y; Wu X; Liu X; Yan G; Xu C
    J Proteome Res; 2010 Dec; 9(12):6180-90. PubMed ID: 21028892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.
    Hong SH; Misek DE; Wang H; Puravs E; Giordano TJ; Greenson JK; Brenner DE; Simeone DM; Logsdon CD; Hanash SM
    Cancer Res; 2004 Aug; 64(15):5504-10. PubMed ID: 15289361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer.
    Li J; Wang LJ; Ying X; Han SX; Bai E; Zhang Y; Zhu Q
    Scand J Immunol; 2012 Mar; 75(3):342-9. PubMed ID: 22010875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.